FDA considers adding a dozen peptides to its bulk drug compounding list RAPS FDA Peptide Reclassification 2026: What It Means for Providers FDA Moves to Exclude Semaglutide, Tizerpatide, and Liraglutide from 503B Bulk Substances List Lengea Peptides are starting to move back into the conversation., After years of restriction under the FDAs 503A Category 2 list, were now seeing momentum toward re evaluation and potential reintroduction When will the FDA reclassify BPC 157 to Category 1? Odds & Predictions